Ranked GEO Datasets

Active GEO index contains 43174 ranked datasets; organism mixed: Homo sapiens (31498), Mus musculus (11676); assay type mixed: microarray (24165), bulk RNA-seq (19008), other assay type (1). Rankings use the Tumor vs normal comparison with transparent suitability, metadata quality, and warning rules.

15 shown of 15 matching datasets Comparison Tumor vs normal Tissue/sample context Patient tissue Organism Homo sapiens Assay bulk RNA-seq Ranking defaults Active 6 active filters Page 1 of 1 · showing 1-15

Disease/condition e.g. colorectal cancer Anatomical source Specimen material Cell population Comparison type Required Organism Assay type Minimum samples Experimental model Exclude cell lines Require processed data GEO only recount3 available Expression Atlas available

Clear filters Ranking defaults Relax defaults

RNA-seq access dataset for epigenomics landscape of colorectal cancer

Organization: Broad Institute of MIT and Harvard

Case tumor sample Control normal tissue

Tumor vs matched normal Tissue

Rationale for Tumor vs normal

Scores and metadata are strong enough for direct review.

Prioritized for patient tissue tumor-vs-normal triage.
Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.
External evidence: PubMed links 1 publication; 1 DOI available: PMID 34059508.

12 samples

No warnings

RNA-seq data of 20 pairs of colorectal tumor with matched adjacent normal colorectal tissue

Organization: Peking University Cancer Hospital

Case tumor sample Control normal tissue

Tumor vs matched normal Tissue

Rationale for Tumor vs normal

Scores and metadata are strong enough for direct review.

Prioritized for patient tissue tumor-vs-normal triage.
Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.
External evidence: PubMed links 4 publications; 4 DOIs available: PMID 37895185, PMID 38306561, PMID 39433800, PMID 39435428.

40 samples

No warnings

The prevalence of human cytomegalovirus in colorectal cancer and viral gene expression profiles

Organization: Second Affiliated Hospital, Wenzhou Medical University

Case tumor sample Control normal tissue

Tumor vs matched normal Tissue

Rationale for Tumor vs normal

Scores and metadata are strong enough for direct review.

Prioritized for patient tissue tumor-vs-normal triage.
Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.

10 samples

No warnings

NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer

Organization: Seoul National University

Case tumor sample Control normal tissue

Tumor vs unmatched normal Tissue

Rationale for Tumor vs normal

Scores and metadata are strong enough for direct review.

Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.
External evidence: PubMed links 1 publication; 1 DOI available: PMID 41476086.

190 samples

No warnings

Tumor immunogenomic features determine outcomes in metastatic colorectal cancer patients treated with standard-of-care combinations of bevacizumab and cetuximab

Organization: University of North Carolina at Chapel Hill

Case tumor sample Control normal tissue

Tumor vs matched normal Tissue

Rationale for Tumor vs normal

Scores and metadata are strong enough for direct review.

Prioritized for patient tissue tumor-vs-normal triage.
Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.
External evidence: PubMed links 1 publication; 1 DOI available: PMID 39779996.

579 samples

No warnings

Transcriptome sequencing of normal intestinal mucosal tissues, paired primary CRC tissues and liver metastases lesions in participants of CRC

Organization: SUN YAT-SEN UNIVERSITY

Case colorectal cancer Control normal tissue

Tumor vs unmatched normal Tissue

Rationale for Tumor vs normal

Scores and metadata are strong enough for direct review.

Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.
External evidence: PubMed links 1 publication; 1 DOI available: PMID 41206062.

52 samples

No warnings

Gene expression profiling study to identify distinct subtypes in Peritoneal metastasis of colorectal cancer

Organization: Ajou University Medical Center

Case tumor sample Control normal tissue

Tumor vs unmatched normal Tissue

Rationale for Tumor vs normal

Scores and metadata are strong enough for direct review.

Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.
External evidence: PubMed links 1 publication; 1 DOI available: PMID 38816545.

33 samples

No warnings

RNA-Seq analysis of tumor and matched normal samples from colorectal cancer patients.

Organization: IMCB

Case tumor sample Control normal tissue

Tumor vs matched normal Tissue

Rationale for Tumor vs normal

Scores and metadata are strong enough for direct review.

Prioritized for patient tissue tumor-vs-normal triage.
Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.
External evidence: PubMed links 1 publication; 1 DOI available: PMID 41803264.

73 samples

No warnings

Downregulation of MGST3 promotes colorectal cancer progression

Organization: Qingdao University

Case tumor sample Control normal tissue

Tumor vs unmatched normal Tissue

Rationale for Tumor vs normal

Scores and metadata are strong enough for direct review.

Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.
External evidence: PubMed links 1 publication; 1 DOI available: PMID 41858713.

14 samples

No warnings

Gene expression profiling study by RNA-seq in colorectal cancer

Organization: Korea Research Institutue of Bioscience & Biotechnology

Case colorectal cancer Control normal tissue

Tumor vs unmatched normal Tissue

Rationale for Tumor vs normal

Scores and metadata are strong enough for direct review.

Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.
External evidence: Expression Atlas curated experiment link is available.
External evidence: PubMed links 19 publications; 18 DOIs available: PMID 25049118, PMID 26109429, PMID 27152521, PMID 31236000, PMID 31578316.

54 samples

No warnings

RNA-Seq analysis of human colorectal cancer with liver metastasis

Organization: Shanghai Tenth People's Hospital

Case tumor sample Control normal tissue

Tumor vs matched normal Tissue

Rationale for Tumor vs normal

Scores and metadata are strong enough for direct review.

Prioritized for patient tissue tumor-vs-normal triage.
Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.
External evidence: PubMed links 1 publication; 1 DOI available: PMID 30241526.

12 samples

No warnings

RNA-seq of CRC tissues

Organization: Fudan University

Case colorectal cancer Control normal tissue

Tumor vs matched normal Tissue

Rationale for Tumor vs normal

Dataset can inform exploration but is not strong enough for primary analysis.

Prioritized for patient tissue tumor-vs-normal triage.
Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.
External evidence: PubMed links 5 publications; 5 DOIs available: PMID 32139701, PMID 36868002, PMID 37076536, PMID 38087342, PMID 40355240.

9 samples

No warnings

KCTD9 inhibits the Wnt/β-catenin pathway by decreasing the level of β-catenin in colorectal cancer

Organization: Lianxin Liu Lab

Case tumor sample Control normal tissue

Tumor vs matched normal Tissue

Rationale for Tumor vs normal

Dataset can inform exploration but is not strong enough for primary analysis.

Prioritized for patient tissue tumor-vs-normal triage.
Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.
External evidence: PubMed links 1 publication; 1 DOI available: PMID 36055981.

3 samples

warning Total sample count is below the minimum needed for two comparison groups.

RNA-seq of two paired normal and cancer tissues in two stage III colorectal cancer patients

Organization: Chang Gung University

Case tumor sample Control normal tissue

Tumor vs unmatched normal Tissue

Rationale for Tumor vs normal

Dataset can inform exploration but is not strong enough for primary analysis.

Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.

4 samples

warning Dataset has fewer than six samples and should not be treated as a high-confidence cohort without manual review.

Transcriptome of normal,paracancerous and cancerous colon tissues based on RNA-seq method

Organization: igenomic

Case mixed disease cohort Control normal tissue

Tumor vs unmatched normal Tissue

Rationale for Tumor vs normal

Dataset can inform exploration but is not strong enough for primary analysis.

Prioritized assay: bulk RNA-seq is the active assay expectation.
Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
Processed data is available for downstream review.
External evidence: PubMed links 1 publication; 1 DOI available: PMID 22905095.

3 samples

warning Total sample count is below the minimum needed for two comparison groups. warning Multiple disease or phenotype arms were detected. The displayed grouping summarizes the full dataset; select the requested disease-specific contrast before analysis.